Skip to content

Eloralintide vs Retatrutide

Updated 9 sources

Key differences

  1. 1Different drugs: eloralintide is amylin only; retatrutide hits GLP-1, GIP and glucagon receptors.
  2. 2Phase 2 at 48 weeks: eloralintide 9 mg -20%; retatrutide 12 mg -24.2%. Separate trials, no head-to-head.

Side by side

Facts from each record, in the same words as their own pages.
Eloralintide and Retatrutide side by side
EloralintideRetatrutide
Category
  • Weight loss
  • GLP-1, Weight loss
Evidence
  • Some human trials
  • Strong human trials
FDA status
  • In clinical trialsRegulatory
  • In clinical trialsRegulatory
WADA
  • Not confirmed
  • Not confirmed
Half-life
  • About 13 to 15 days (310 to 366 hours) after single doses of 0.04 to 12 mg in healthy adults; levels peak 72 to 132 hours after a shot.Clinical study
  • About 6 days in the phase 1b trial, with exposure rising in proportion to dose. Built for once-weekly shots.Clinical study
Routes
  • Subcutaneous injection
  • Subcutaneous injection
Forms
  • Vial (powder)
Not reported
Reported doses
  • 0.5 to 12 mg (subcutaneous injection)
  • 0.25 to 12 mg (subcutaneous injection)
Most cited frequency
  • Once weekly at 1, 3, 6 or 9 mg depending on arm
  • Once weekly. Start at 2 mg, step up every 4 weeks to a target of 4, 9 or 12 mg, then hold.
Vial sizes
  • 10 mg, 30 mgVendor guide
  • 5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 40 mg, 50 mg, 60 mgCompetitor guide
Mixed vial keeps
  • Fridge at 2 to 8 °C, protected from light.Vendor guide
  • Keep the mixed vial in the fridge and use it within about 28 days.Community-reported
Protocols on file
  • 8
  • 18

Doses shown are what sources report, labelled by origin. Not medical advice.

Read each in full

Sources

9 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.